Iradimed (NASDAQ:IRMD – Get Free Report) was upgraded by StockNews.com from a “buy” rating to a “strong-buy” rating in a research note issued on Tuesday.
Iradimed Stock Up 1.3 %
Shares of IRMD traded up $0.77 during trading hours on Tuesday, hitting $60.70. 23,632 shares of the company were exchanged, compared to its average volume of 37,849. Iradimed has a fifty-two week low of $40.18 and a fifty-two week high of $61.24. The company has a market cap of $769.07 million, a price-to-earnings ratio of 41.58 and a beta of 0.81. The firm’s fifty day moving average is $55.60 and its 200 day moving average is $50.98.
Insider Activity at Iradimed
In related news, CFO John Glenn sold 2,500 shares of the stock in a transaction that occurred on Monday, December 2nd. The shares were sold at an average price of $54.18, for a total value of $135,450.00. Following the completion of the transaction, the chief financial officer now owns 4,383 shares of the company’s stock, valued at $237,470.94. This represents a 36.32 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 37.10% of the stock is currently owned by insiders.
Institutional Inflows and Outflows
About Iradimed
IRadimed Corp. engages in the development, manufacture, marketing, and distribution of Magnetic Resonance Imaging compatible medical devices. It also provides a non-magnetic Intravenous infusion pump system that is specifically designed for use during MRI procedures. The company was founded by Roger Susi in July 1992 and is headquartered in Winter Springs, FL.
Recommended Stories
- Five stocks we like better than Iradimed
- Investing in the High PE Growth Stocks
- Survey Reveals: Top 150 Best Coffee Shops for Remote Workers and Business Deals [2025]
- Are Penny Stocks a Good Fit for Your Portfolio?
- What Does the Future Hold for Eli Lilly?
- 3 Best Fintech Stocks for a Portfolio Boost
- Oracle Stock Drops Nearly 14% – Is Now the Time to Buy?
Receive News & Ratings for Iradimed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iradimed and related companies with MarketBeat.com's FREE daily email newsletter.